Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Stoke Therapeutics Inc STOK

Healthcare Biotechnology
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:STOK)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire 12 hours ago

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Business Wire 11 days ago

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Business Wire April 29, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Business Wire April 17, 2024

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Business Wire April 4, 2024

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Business Wire March 27, 2024

Stoke Therapeutics Announces Proposed Public Offering

Business Wire March 26, 2024

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Business Wire March 25, 2024

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire March 25, 2024
View More News ››

Opinion & Analysis (NDAQ:STOK)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:STOK)

Where are the Opportunities in (STOK)

Just In: $STOK Where are the Opportunities in (STOK)2024-04-17 00:46:00 ET Stock Traders Daily has produced this trading report using a...
whytestocks - April 17, 2024

$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀

iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver...
Saaaa1 - May 6, 2021

watching this one for

an entry point price of around $19 per share is a much better price for me.
coolfooldumbguy - June 19, 2019
View more Bullboard ››

Multi-Metal Development Ltd

Multi-Metal Development Ltd

Multi-Metal Development Ltd is a Canada-based mining company. The Company's projects consist of CuMo Project in Idaho and ...
View More »